A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038)
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2013
At a glance
- Drugs Dasatinib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 20 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 08 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.